NCT03309150 2024-11-29
ATRi Transition Rollover Study
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
Clinical Trials
3 trialsNCT02723864 2022-02-08
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02157792 2020-04-01
M6620 First in Human Study
EMD Serono
Phase 1 Completed